14.359 articles found

Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells.

Stefanis L, Kholodilov N, Rideout HJ, Burke RE, Greene LA.

J Neurochem · 2001-02-01

DOI: 10.1046/j.1471-4159.2001.00114.xPMID: 11181836

Mutations in the alpha-synuclein gene in Parkinson's disease among Indians.

Nagar S, Juyal RC, Chaudhary S, Behari M, Gupta M, Rao SN, Thelma BK.

Acta Neurol Scand · 2001-02-01

DOI: 10.1034/j.1600-0404.2001.103002120.xPMID: 11227130

From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.

Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA.

Philos Trans R Soc Lond B Biol Sci · 2001-02-01

DOI: 10.1098/rstb.2000.0767PMID: 11260802

The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.

Bonifati V, De Michele G, Lücking CB, Dürr A, Fabrizio E, Ambrosio G, Vanacore N, De Mari M, Marconi R, Capus L, Breteler MM, Gasser T, Oostra B, Wood N, Agid Y, Filla A, Meco G, Brice A, Italian PD Genetics Study Group, French PD Genetics Study Group, European Consortium on Genetic Susceptibility in PD.

Neurol Sci · 2001-02-01

DOI: 10.1007/s100720170042PMID: 11487197

Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease.

Ferrarese C, Tremolizzo L, Rigoldi M, Sala G, Begni B, Brighina L, Ricci G, Albizzati MG, Piolti R, Crosti F, Dalprà L, Frattola L.

Neurol Sci · 2001-02-01

DOI: 10.1007/s100720170049PMID: 11487204

Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients.

Petrozzi L, Lucetti C, Gambaccini G, Bernardini S, Del Dotto P, Migliore L, Scarpato R, Bonuccelli U.

Neurol Sci · 2001-02-01

DOI: 10.1007/s100720170058PMID: 11487213

The genetic causes of neurodegenerative diseases.

Hardy J.

J Alzheimers Dis · 2001-02-01

DOI: 10.3233/jad-2001-3115PMID: 12214079

Evidence for a partially folded intermediate in alpha-synuclein fibril formation.

Uversky VN, Li J, Fink AL.

J Biol Chem · 2001-01-10

DOI: 10.1074/jbc.m010907200PMID: 11152691

Treatment of Parkinson^s disease by genetically modified immortalized fibroblasts

Xu Dehua, Chen Xianwen, Xu Lingfei, Cao Lei, Chen Shengdi, Liu Xinyuan, Zheng Zhongcheng.

Acta Biochimica et Biophysica Sinica · 2001-01-01

The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.

Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jäkälä P, Beyreuther K, Masters CL, Li QX.

J Neurochem · 2001-01-01

DOI: 10.1046/j.1471-4159.2001.00021.xPMID: 11145981

Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.

Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y.

Brain Res · 2001-01-01

DOI: 10.1016/s0006-8993(00)03082-1PMID: 11150486

Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element.

Touchman JW, Dehejia A, Chiba-Falek O, Cabin DE, Schwartz JR, Orrison BM, Polymeropoulos MH, Nussbaum RL.

Genome Res · 2001-01-01

DOI: 10.1101/gr.165801PMID: 11156617